Latest Capital Raising And Funding News

RLF AgTech Ltd has reported a remarkable financial turnaround in FY25, with revenues more than doubling and losses narrowing significantly, setting the stage for expansion in FY26.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Assetora Limited reported a reduced loss of $3.35 million for FY2025 despite an 18% revenue decline, focusing on capital raising and fund growth to stabilize operations.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

IMEXHS Limited reported a $3 million net loss for the half-year ending June 2025, driven by a significant goodwill impairment, while annualised recurring revenue rose 11%. The company completed a $2.6 million capital raise to support growth amid ongoing cost optimisation and automation efforts.

Thrive Tribe Technologies has raised approximately $250,000 through a discounted share placement, aiming to bolster its working capital. The move reflects ongoing efforts to support its health and wellness digital platform.

Cyprium Metals unveils a rapid restart plan for its Nifty Copper Complex, backed by a substantial A$80 million capital raise to fund early cash flow and long-term growth. The project boasts a pre-tax NPV of A$1.1 billion, positioning Cyprium as a compelling copper play on the ASX.

CurveBeam AI Limited posted a strong 85% increase in revenue to $12.1 million for FY25, alongside a reduced net loss of $16.8 million. Despite operational improvements and a recent $11.58 million capital raise, the company flags material uncertainty over its ability to continue as a going concern.

Centaurus Metals Limited has opened a Share Purchase Plan (SPP) to raise up to AUD 3 million by offering shares at a 20% discount, accompanied by free attaching options. This initiative complements a recent $20 million placement to institutional investors and aims to fund key nickel and copper projects in Brazil.

Arovella Therapeutics reported a 14% reduction in net loss to $7.5 million for FY25, bolstered by a $15 million capital raise to fund its lead iNKT cell therapy program progressing toward a pivotal phase 1 clinical trial.

IPH Limited reported a 13.2% rise in net profit after tax to $68.8 million for FY25, driven by strategic acquisitions in Canada and organic growth across Asia-Pacific. Revenue surged 16.5% to $710.3 million despite inflationary pressures and operational challenges.

St Barbara Limited reported a $52 million underlying loss for FY25, driven by investments in its Simberi Expansion Project and operational challenges. The company classified its Atlantic operations as discontinued, recognizing a $38 million impairment, while completing a $100 million capital raise to support growth.